AMGN vs. ICLR: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at AMGN and ICLR, comparing key factors like performance, valuation metrics, dividends, and financial strength.
Company Overview
AMGN’s market capitalization of 156.11 billion USD is substantially larger than ICLR’s 11.23 billion USD, indicating a significant difference in their market valuations.
ICLR carries a higher beta at 1.16, indicating it’s more sensitive to market moves, while AMGN (beta: 0.50) exhibits greater stability.
| Symbol | AMGN | ICLR |
|---|---|---|
| Company Name | Amgen Inc. | ICON Public Limited Company |
| Country | US | IE |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Diagnostics & Research |
| CEO | Mr. Robert A. Bradway | Dr. Steven A. Cutler MBA, Ph.D. |
| Price | 290.33 USD | 139.11 USD |
| Market Cap | 156.11 billion USD | 11.23 billion USD |
| Beta | 0.50 | 1.16 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 17, 1983 | May 15, 1998 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of AMGN and ICLR over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
This section compares the market valuation of AMGN and ICLR. Key takeaways regarding their valuation, when viewed within their industry context, are presented in the commentary that follows.
- AMGN’s Forward PEG ratio of 7.43 is very high. This suggests that investors have priced in a substantial amount of future earnings growth, potentially making the stock vulnerable if these high expectations are not met or if growth slows.
- AMGN’s Price-to-Book (P/B) ratio of 25.16 is very high. This often indicates that the market values the company significantly above its net asset value, usually reflecting strong profitability, valuable intangible assets (like brand or patents), or high expectations for future growth.
| Symbol | AMGN | ICLR |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 26.33 | 15.01 |
| Forward PEG Ratio (TTM) | 7.43 | 1.65 |
| Price-to-Sales Ratio (P/S, TTM) | 4.57 | 1.37 |
| Price-to-Book Ratio (P/B, TTM) | 25.16 | 1.20 |
| EV-to-EBITDA (TTM) | 16.53 | 9.29 |
| EV-to-Sales (TTM) | 6.00 | 1.74 |
Dividend Comparison
AMGN provides a 3.19% dividend yield, potentially offering a blend of income and growth, whereas ICLR currently does not pay a dividend, possibly retaining profits to fund operations or growth initiatives.
| Symbol | AMGN | ICLR |
|---|---|---|
| Dividend Yield (TTM) | 3.19% | 0.00% |
Financial Strength Metrics Comparison
This section evaluates the financial strength of AMGN and ICLR. Noteworthy observations on their financial resilience, considered from an industry perspective, are detailed in the points that follow.
- AMGN’s Debt-to-Equity (D/E) ratio of 9.24 is very high. This indicates that the company is significantly financed by debt, which can amplify returns but also substantially increases its financial risk profile and vulnerability to earnings fluctuations.
| Symbol | AMGN | ICLR |
|---|---|---|
| Current Ratio (TTM) | 1.17 | 1.27 |
| Quick Ratio (TTM) | 0.88 | 1.27 |
| Debt-to-Equity Ratio (TTM) | 9.24 | 0.37 |
| Debt-to-Asset Ratio (TTM) | 0.64 | 0.21 |
| Net Debt-to-EBITDA Ratio (TTM) | 3.92 | 1.98 |
| Interest Coverage Ratio (TTM) | 3.19 | 5.09 |